No discussion of the HCV arena would be complete without Bavituximab, so here is PPHM’s latest PR: http://finance.yahoo.com/news/Peregrine-Presents-Phase-Ib-iw-304801467.html?x=0&.v=1 (The above is facetious, of course.)